- Home
- RCUS vs ARQT Comparison
RCUS vs ARQT Comparison
Compare RCUS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- ARQT
- Stock Information
- Founded
- RCUS 2015
- ARQT 2016
- Country
- RCUS United States
- ARQT United States
- Employees
- RCUS N/A
- ARQT N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- RCUS Health Care
- ARQT Health Care
- Exchange
- RCUS Nasdaq
- ARQT Nasdaq
- Market Cap
- RCUS 906.4M
- ARQT 1.7B
- IPO Year
- RCUS 2018
- ARQT 2020
- Fundamental
- Price
- RCUS $9.38
- ARQT $15.00
- Analyst Decision
- RCUS Buy
- ARQT Strong Buy
- Analyst Count
- RCUS 9
- ARQT 6
- Target Price
- RCUS $20.86
- ARQT $18.80
- AVG Volume (30 Days)
- RCUS 1.1M
- ARQT 2.0M
- Earning Date
- RCUS 08-07-2025
- ARQT 08-13-2025
- Dividend Yield
- RCUS N/A
- ARQT N/A
- EPS Growth
- RCUS N/A
- ARQT N/A
- EPS
- RCUS N/A
- ARQT N/A
- Revenue
- RCUS $141,000,000.00
- ARQT $212,819,000.00
- Revenue This Year
- RCUS N/A
- ARQT $61.15
- Revenue Next Year
- RCUS $28.73
- ARQT $37.98
- P/E Ratio
- RCUS N/A
- ARQT N/A
- Revenue Growth
- RCUS N/A
- ARQT 100.03
- 52 Week Low
- RCUS $6.50
- ARQT $7.86
- 52 Week High
- RCUS $18.98
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- RCUS 57.71
- ARQT 60.23
- Support Level
- RCUS $8.03
- ARQT $13.06
- Resistance Level
- RCUS $9.97
- ARQT $15.36
- Average True Range (ATR)
- RCUS 0.47
- ARQT 0.66
- MACD
- RCUS 0.11
- ARQT 0.12
- Stochastic Oscillator
- RCUS 71.32
- ARQT 82.57
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.